Results per Page:
Dr. Yeon Soo Kim receives NIH Pathway to Independence Award
Hsieh Lab postdoctoral fellow studies how advanced prostate cancer evades therapy by altering the way RNA builds proteins
Conducting RNA reconnaissance
Fred Hutch researchers invent a CRISPR screening method to understand RNA-binding proteins often mutated in cancer and other diseases
Finding a new way to break the supply chain fueling advanced prostate cancer
Fred Hutch researcher wins a $1M grant for a London-Seattle collaboration to find new therapies for drug-resistant prostate cancer
Fred Hutch and UW hematology-oncology fellows win ASCO Young Investigator Awards
Winners represent broad range of research
Bridging the gap between cancer drug target and cancer drug
Fred Hutch RNA-translation expert Dr. Andrew Hsieh receives Harrington Scholar-Innovator Award to develop experimental compound into anti-cancer drug
RNA stability may play a role in prostate cancer
New research links mutations in RNA region that helps regulate protein production to progression and drug resistance
A seesaw between transcription and translation restrains bladder carcinogenesis
From the Hsieh Lab, Human Biology Division
Researchers discover molecular fail-safe that keeps bladder tissues from turning cancerous
Bladder cells’ strategy blocks cancer-causing genetic programs, could be new therapeutic target
Tracking prostate cancer dynamics
Single-cell study brings prostate tumors into focus and highlights potential treatment target: cancer complexity
Dr. Andrew Hsieh elected member of American Society for Clinical Investigation
Physician-scientist demonstrated central role protein synthesis plays in cancer
Hopes and predictions for 2022
Hutch researchers look ahead to an increase in cancer screening, improved vaccines and greater trust in science
Untranslated, maybe, unappreciated, no more.
From the Hsieh Lab, Human Biology Division
Overlooked stretches of DNA could hide cancer-causing mutations
New cutting-edge technique sheds light on difficult-to-study DNA regions, potential drug targets